Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VIII and IX inhibitors

Thrombosis Research

Volumn 95, Issue 4 SUPPL. 1, 1999, Pages

  Barthels, Monika ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acquired hemophilia; Factor IX inhibitors; Factor VIII inhibitors; Prothrombin complex concentrates; Recombinant factor VIIa; Side effects

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 COMPLEX; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; CLINICAL TRIAL; HEMOPHILIA; HUMAN; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; VIRUS TRANSMISSION;

EID: 0032820649     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00082-1     Document Type: Article

References (74)

1. Breen F.A., Tullis J.L. Prothrombin concentrates in treatment of Christmas disease and allied disorders. JAMA. 208:1969;1848-1852.
2. Fekete LF, Holst SL, Peetom F, Deveber LL. Auto-factor IX concentrate: A new therapeutic approach to treatment of haemophilia A patients with inhibitors. 14th Intern. Congress of Hematology. Brazil, 1972, A295.
3. Kurczynsky E.M., Penner J.A. Activated prothrombin concentrate for patients with factor VIII inhibitors. N Engl J Med. 291:1974;164-167.
4. Preston F.E., Dinsdale R.C.W., Sutcliffe D.J., Bardhan G., Wyld P.J., Hamlyn J.F. Factor VIII inhibitor by-passing activity (FEIBA) in the management of patients with factor VIII inhibitors. Thromb Res. 11:1977;643-651.
5. Nowotny C., Lechner K., Niessner H., Thaler E. Effect of in vivo administration of FEIBA on clotting tests. Dose-response relationship. Thromb Haemost. 42:1979;A199.
6. Aronson D.L., Bagley J. Preliminary characterization of factor VIII bypassing coagulant. Ann NY Acad Sci. 370:1981;291-302.
7. Lechler E. Prothrombinkomplexkonzentrate (Faktor II-VII-IX-X-Komplex). Eigenschaften und klinische Anwendung. Hämostaseologie. 2:1982;116-127.
8. Hedner U. Factor VIIa in the treatment of haemophilia. Review paper. Blood Coag Fibrinolysis. 1:1990;307-317.
9. Lechner K. Aktivierte Prothrombinkomplexkonzentrate. Hämostaseologie. 2:1982;110-115.
10. Lechner K. Hämophilie. In: Heene DL, editor. Handbuch der Inneren Medizin. Bd. II/9 Blutgerinnung und hämorrhagische Diathesen II: Angeborene und erworbene Koagulopathien. Berlin Heidelberg: Springer Verlag; 1985. p. 12-175.
11. Nilsson I.M., Berntorp E., Freiburghaus C. Treatment of patients with factor VIII and IX inhibitors. Thromb Haemost. 70:1993;56-59.
12. Feinstein DI. Acquired inhibitors against factor VIII and other clotting proteins. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, editors. Hemostasis and thrombosis. Basic principles and clinical practice, 3d ed. Philadelphia: Lippincott Co.; 1994. p. 831.
13. Brettler D.B. Inhibitors in congenital haemophilia. Baillière's Clinical Haematology. 9:1996;319-329.
14. Green D., Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost. 45:1981;200-203.
15. Huhmann I., Lechner K. Spontane Faktor VIII-Inhibitoren. Hämostaseologie. 16:1996;164-170.
16. Scharrer I. Erworbene Inhibitoren gegen Faktor IX. Hämostaseologie. 16:1996;171-173.
17. Aledort L. Inhibitors of hemophilia patients. Current status and management Am J Hemat. 47:1994;208-217.
18. Kasper C.K., Aledort L., Aronson D., Counts R., Edson J.R., van Eys J., Fratantoni J., Green D., Hampton J., Hilgartner M., Levine P., Lazerson J., McMillan C., Penner J., Shapiro S., Shulman N.R. A more uniform measurement of factor VIII inhibitors. Thrombos Diathes Haemorr. 34:1975;612.
19. Meili E. Antikörper mit "Antiphospholipid"-Spezifität können bei Hämophilen mit chronischer Hepatopathie Faktor VIII-Hemmkörper vortäuschen. In: Landbeck G, Marx R, editors. 12. Hämophiliesymposium Hamburg 1981. Hamburg, Germany: Stuttgart, New York: Schattauer; 1986. p. 113-5.
20. Allain J.P., Frommel D. Antibodies to factor VIII. V. Patterns of immune response to factor VIII in hemophilia A. Blood. 47:1976;973-982.
21. Sjamsoedin L.J.M., Heijnen L., Mauser-Bunschooten E.P., van Geijswijk J.L., van Houwelingen H., van Asten P., Sixma J.J. The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A randomised double-blind clinical trial. N Engl J Med. 305:1981;717-721.
22. Lusher J.M., Shapiro S.S., Palascak J.E., Rao A.V., Levine P.H., Baltt P.M. Efficacy of prothrombin complex concentrates in hemophiliacs with antibodies for factor VIII. A multicenter trial. N Engl J Med. 303:1980;421-425.
23. Hilgartner M., Knatterud G.L., FEIBA study group The use of factor eight inhibitor bypassing activity (FEIBA Immuno) product of treatment of bleeding episodes in hemophiliacs with inhibitors. Blood. 11:1983;36-40.
24. Hilgartner M., Aledort L., Andes A., Gill J., FEIBA study group Efficacy and safety of vapor heated anti-inhibitor coagulant complex in hemophilia patients. Transfusion. 30:1990;626-630.
25. Abildgaard C.F., Penner J., Watson-Williams E. Anti-inhibitor coagulant complex (autoplex) for treatment of factor VIII inhibitors in hemophilia. Blood. 56:1980;978-984.
26. Giddings J.C., Bloom A.L., Kelly M.A., Spratt H.C. Human factor IX inhibitors. Immunochemical characteristics and treatment with activated concentrate. Clin Lab Haemat. 5:1983;165-175.
27. Mariani G., Russo M.A., Mandelli F. Activated prothrombin complex concentrates. 1982;Praeger, New York.
28. Iizuka A., Kuwashima M., Nagao T. Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX. Nippon Ketsueki Gakkai Zasshi. 45:1982;987-992.
29. Buchanan G., Kevy S. Use of prothrombin complex concentrates in hemophiliacs with inhibitors. Clinical and laboratory studies Pediatrics. 62:1978;767-771.
30. Hoots W.K., Snyder M.S., McMillan C.S. Effects of activated prothrombin complex concentrates (APCC)L for craniospinal hemorrhage in classic haemophiliacs with factor VIII inhibitors. Ped Res. 14:1980;535-538.
31. Sultan Y., Brouet J.C., Debre P. Treatment of inhibitor to factor VIII with activated prothrombin complex concentrate. N Engl J Med. 291:1974;1087.
32. Mannucci P.M., Federicci A., Vignano S., Cattaneo M. Multiple dental extractions with a new prothrombin complex concentrate in two patients with factor VIII inhibitors. Thromb Res. 15:1979;359-364.
33. Hanna W.T., Madigan R.R., Miles M.A., Lange R.D. Activated factor IX complex in treatment of surgical cases of hemophilia A with inhibitors. Thromb Haemost. 46:1981;638-641.
34. Stenbjerg S., Tauris P., Skottun T., Jørgensen J. Total dental extraction in a patient with factor VIII inhibitor. Thromb Res. 18:1980;889-893.
35. Christiansen S.E., Ingerslev J., Wallevik K., Farso F., Helmig O., Stenbjerg S. Management of anterior compartment syndrome in two high responder factor VIII inhibitor patients with activated prothrombin complex concentrate. Thromb Res. 42:1986;707-712.
36. Schramm W. Konsensus-Empfehlungen zur Hämophiliebehandlung in Deutschland. Hämostaseologie. 14:1994;81-83.
37. Barthels M, Schramm W. Faktor VIII-/von Willebrand Faktor Konzentrate, Faktor IX-Konzentrate. In: Vorstand und wissenschaftlicher Beirat der Bundesärztekammer, editor. Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Köln: Deutscher Ärzteverlag; 1995. p. 99-115.
38. Pollock A., Lewis J.M. Factor VIII inhibitor bypassing activity. Lancet. II:1976;43-44.
39. Lusher J.M. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol. 28(Suppl 6):1991;3-5.
40. Söhngen D., Köster W., Kuntz B.M., Glueck S., Schneider W. Three cases of acquired factor VIII:C inhibitors in non-hemophilic patients. Klin Wochenschr. 68:1990;1071-1075.
41. Kasper C.K. Postoperative thrombosis in hemophilia B. N Engl J Med. 289:1973;160.
42. Gruppo R.A., Bove K.E., Donaldson V.H. Fatal myocardial necrosis associated with prothrombin complex concentrate therapy in hemophilia A. N Engl J Med. 309:1983;242-243.
43. Stenbjerg S., Jørgensen J. Disseminated intravascular coagulation and infusion of factor VIII bypassing activity. Lancet. I:1977;360.
44. Agrawal B.L., Zelkowitz L., Hletko P. Acute myocardial infarction in a young hemophilic patient during therapy with factor IX concentrate and epsilon amino caproic acid. J Pediatr. 98:1981;931-933.
45. Fuerth J.H., Mahrer P. Myocardial infarction after factor IX therapy. JAMA. 245:1981;1455-1456.
46. Sullivan D.W., Purdy L.J., Billingham M., Glader B.E. Fatal myocardial infarction following therapy with prothrombin complex concentrates in a young man with hemophilia A. Pediatrics. 74:1984;279-281.
47. Chistolini A., Mazzucconi M.G., Tirindelli M.C., La Erde G., Ferrari A., Mandelli F. Disseminated intravascular coagulation and myocardial infarction in a hemophilia B patient during therapy with prothrombin complex concentrates. Acta Haematol. 83:1990;163-165.
48. Green D., Snapper H., Abu-Jawdeh G., Reddy J. Acute myocardial infarction, non-bacterial thrombotic endocarditis, and disseminated intravascular coagulation in a severe hemophiliac. Am J Hematol. 35:1990;210-212.
49. Köhler M., Heiden M., Harbauer G., Miyashita C., Mörsdorf S., Braun B., Ernert P., Wenzel E., Rose S., Pindur G. Comparison of different prothrombin complex concentrates - in vitro and in vivo studies. Thromb Res. 60:1990;63-70.
50. Hellstern P., Beeck H., Fellhauer A., Fischer A., Faller-Stöckl B., for the PCC Study Group Factor VII and activated factor VII content of prothrombin complex concentrates. Vox Sang. 73:1997;155-161.
51. Schimpf K., Zeltsch C.H., Zeltsch P. Myocardial infarction complicating activated prothrombin complex concentrate substitution in patients with haemophilia A. Lancet. 2:1982;1043.
52. Chavin S.I., Siegel D.M., Rocco T.A., Olson J.P. Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. Am J Med. 85:1988;245-249.
53. Rodeghiero F., Castronovo S., Dini E. Disseminated intravascular coagulation after infusion of FEIBA (factor VIII inhibitor bypassing activity) in a patient with acquired hemophilia. Thromb Haemost. 48:1982;339-340.
54. Rasche H., Bindewald H., Köhler W., Scheck R., Heinrich R., Seibert K. Notfallbehandlung von Blutungskomplikationen bei Hemmkörper-Hämophilie mit aktivierten Prothrombinkomplexkonzentraten. Dtsch Med Wschr. 102:1977;319-323.
55. Fukui H., Fujimura Y., Takamashi Y., Mikami S., Yoshioka A. Laboratory evidence of DIC under FEIBA treatment of a hemophiliac patient with intracranial bleeding and high titre factor VIII inhibitor. Thromb Res. 22:1981;177-184.
56. Mizon P., Goudemand J., Jude B., Marey A. Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor. Ann Hematol. 64:1992;309-311.
57. Mannucci P.M., Bader R., Ruggieri Z.M. Concentrates of clotting factor IX. Lancet. I:1976;41.
58. Lechner K., Nowotny C., Krinninger B., Zegner M., Deutsch E. The effect of treatment with activated prothrombin complex concentrate (FEIBA) on factor VIII antibody level. Thromb Haemost. 40:1978;478-485.
59. Barrowcliffe T.W., Kemball-Cook G., Gray E. Factor VIII inhibitor bypassing activity. A suggested mechanism of action Thromb Res. 21:1981;181-186.
60. Lindley C.M., Sawyer W.T., Macik B.G., Lusher J., Harrison J.F., Baird-Cox K., Birch K., Glazer S., Roberts H.R. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 55:1994;638-648.
61. Schulman S., Bech Jensen M., Varon D., Keller N., Gitel S., Horoszowski H., Heim M., Martinowitz U. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost. 75:1996;432-436.
62. Yoshida A., Nishio K., Shima M. Thrombelastogram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII. Haemostasis. 26(Suppl 1):1996;139-142.
63. Hedner U. Dosing and Monitoring NovoSeven treatment. Haemostasis. 26(Suppl 1):1996;102-108.
64. Morrissey J.H. Plasma factor VIIa. Measurement and potential clinical significances Haemostasis. 26(Suppl 1):1996;66-71.
65. Hedner U., Glazer S., Pingel K., Alberts K.A., Blombäck M., Schulman S., Johnsson H. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet. II:1988;1193.
66. Schmidt M.L., Smith H.E., Gamerman S., Dimichele D., Glazer S., Scott J.P. Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor IX-deficient patient with an inhibitor. Br J Haematol. 78:1991;460-463.
67. Bergmann F., Hoyer P.F., Barthels M. Rescue treatment with recombinant factor VIIa (rFVIIA) in a hemophilia B patient with inhibitor. Ann Hemat. 70(Suppl IA):1995;144.
68. Ingerslev J., Freidman D., Gastineau D., Gilchrist G., Johnsson H., Lucas G., McPherson J., Preston E., Scheibel E., Shulman M. Major surgery in hemophiliac patients with inhibitors using recombinant factor VIIa. Haemostasis. 26(Suppl 1):1996;118-123.
69. Lusher J.M. Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis. 26(Suppl 1):1996;124-130.
70. Rice K.M., Savidge G.F. Novoseven® (recombinant factor VIIa) in central nervous bleeds. Haemostasis. 26(Suppl 1):1996;131-134.
71. Mølskov Bech R. Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis. 26(Suppl 1):1996;135-138.
72. Hay C.R.M., Negrier C., Ludlam C.A. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa. A multicenter study Thromb Haemost. 78:1997;1422-1430.
73. Lund-Hansen T. Novoseven - virus safety. Haemostasis. 26(Suppl 1):1996;96-97.
74. Nicolaisen E.M. Long term follow-up with regard to potential immunogenicity. Clinical experience with Novoseven (recombinant factor VIIa) Haemostasis. 26(Suppl 1):1996;98-101.